Indication
advanced refractory solid tumors
5 clinical trials
3 products
1 drug
Clinical trial
A Phase I Study of Safety, Tolerability and Pharmacokinetics of T-1101 (Tosylate) Capsules in Subjects With Advanced Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Product
T-1101Product
CB-03-10Clinical trial
Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid TumorsStatus: Completed, Estimated PCD: 2019-06-24
Clinical trial
A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid TumorsStatus: Terminated, Estimated PCD: 2019-10-01
Clinical trial
Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)Status: Recruiting, Estimated PCD: 2024-11-01
Product
TalazoparibDrug
Selinexor